Changes in cigarette consumption in psychiatric patients: Impact on side-effects or the efficacy of clozapine and olanzapine

Acta Neuropsychiatrica

Volumn 20, Issue 6, 2008, Pages 324-326

  Jain, Subodh ^a   Chawla, Jatinder M ^a,b,c   Theethira, Thimmaiah G ^a   Strassnig, Martin ^a   Chengappa, K N Roy ^a,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b DR RAM MANOHAR LOHIA HOSPITAL   (India)

^c Mayview State Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NORCLOZAPINE; OLANZAPINE; PLACEBO;

ADULT; ANAMNESIS; BIPOLAR I DISORDER; CASE REPORT; CIGARETTE SMOKING; CLINICAL FEATURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; HYPERSALIVATION; MALE; NOTE; SCHIZOPHRENIA; SEIZURE; SMOKING CESSATION;

EID: 57649177355     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1111/j.1601-5215.2008.00345.x     Document Type: Note

References (22)

1. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. JAMA 2000 284 : 2606 2610.
2. Gonzalez-Pinto A, Gutierrez M, Ezcurra J et al. Tobacco smoking and bipolar disorder. J Clin Psychiatry 1998 59 : 225 228.
3. Uçok A, Polat A, Bozkurt O, Meteris H. Cigarette smoking among patient with schizophrenia and bipolar disorders. Psychiatry Clin Neurosci 2004 58 : 434 437.
4. Dudass MM, George TP. Non-nicotine pharmacotherapies for nicotine dependence. Essent Psychopharmacol 2005 6 : 158 172.
5. Strassnig M, Brar JS, Ganguli R. Increased caffeine and nicotine consumption in community-dwelling patients with schizophrenia. Schizophr Res 2006 86 : 269 275.
6. Shrenk D, Brockmeier D, Morike K et al. A distribution study of CYP1A2 phenotypes among smokers & non smokers in a cohort study of healthy Caucasian volunteers. Eur J Clin Pharmacol 1998 53 : 361 367.
7. Meyer JM. Individual changes in clozapine levels after smoking cessation: results and a predictive model. J Clin Psychopharmacol 2001 21 : 569 574.
8. Skogh E, Reis M, Dahl ML, Lundmark J, Bengtsson F. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in naturalistic clinical setting. Ther Drug Monit 2002 24 : 518 526.
9. Zullino DF, Delessert D, Eap CB, Preisig M, Baumann P. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol 2002 17 : 141 143.
10. Bertilsson L, Carrillo JA, Dahl ML et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994 38 : 15 22.
11. Ozdemir V, Kalow W, Posner P et al. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite norclozapine steady state concentration in patients with schizophrenia. J Clin Psychopharmacol 2001 21 : 398 407.
12. Eiermann B, Engel G, Johansson I et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997 44 : 439 446.
13. Seppala NH, Leinonen EVJ, Lehtonen ML et al. Clozapine serum concentrations are lower in smoking than in non smoking schizophrenia patients. Pharmacol Toxicol 1999 85 : 244 246.
14. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet 1999 36 : 425 438.
15. Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ. Influence of dose, cigarette smoking, age, sex and metabolic activity on plasma clozapine concentrations.: a predictive model and nomograms to aid clozapine dose adjustments and to assess compliance in individual patients. J Clin Psychopharmacol 2004 24 : 70 78.
16. Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 2004 76 : 178 184.
17. Byerly MJ, DeVane CL. Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol 1996 16 : 177 187.
18. Skogh E, Bengtsson F, Nordin C. Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report. Ther Drug Monit 1999 21 : 580 582.
19. George TP, Vessicchio JC, Termine A et al. A placebo-controlled study of buproprion for smoking cessation in schizophrenia. Biol Psychiatry 2002 52 : 53 61.
20. Evins AE, Cather C, Deckersbach T et al. A double-blind placebo-controlled trial of buproprion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol 2005 25 : 218 225.
21. Relling MV, Lin JS, Ayers GD, Evans WE. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992 52 : 643 658.
22. Berk M, Should we be targeting smoking cessation as a routine intervention? Acta Neuropsychiatr 2007 19 : 131 132.